By Charles T. Saldarini, CEO, Sentrx With the biopharmaceutical industry’s increasing emphasis on safety, global adverse event (AE) management is receiving renewed attention. The challenge…
By Dax Kiger, director of strategic development, UniversalProcon & Trifecta Multimedical A clinical study manager recently wrote to me and asked, “What is the ideal…
By Mark P. Wade, global practice leader, Lionbridge Life Sciences Pharmaceutical companies have long recognized the complexity of juggling multiple variables at the outset of…
By Bill Allbee, PMP, founder & principal consultant, ABS Pharma Projects, LLC Life sciences product development has been described as navigating a path through a…
By Ross Bjella, president, Mark Wiesman, COO and Dan Dietz, VP of fonanace, DDN According to Karl Pichler, an associate at Stern Stewart — the…
By Efraim Roe, executive director of medical devices, and Patrick Young, executive director of clinical monitoring services, Premier Research Group Medical device companies are outsourcing…
By Joshua Schultz, coporate VP of clinical research services, PAREXEL International The pressure to accelerate time-to-market for innovative biopharmaceutical products has never been more intense.…
By Rick Lapointe, VP of technology, OsoBio As everyone knows by now, the world is in a crisis due to the pandemic outbreak of the…
By James Weston, senior VP of regulatory affairs and quality, and Susan Flint, senior VP of drug development, Talaris Advisors, LLC There are far too…